CLYYF (Celyad Oncology) OCF Margin %: -53,075.00% (As of Dec. 2025)


CLYYF Celyad Oncology SA CLYYF
28 GF Score
Price $0.25
GF Value $0.15
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Celyad Oncology OCF Margin %?

Celyad Oncology CLYYF 28 OCF Margin % is -53,075.00% as of Dec. 2025. GuruFocus rates CLYYF with a GF Score™ of 28/100 and a GF Value™ of $0.15 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 959 Biotechnology companies, Celyad Oncology ranks worse than 96.77% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Celyad Oncology's Cash Flow from Operations for the six months ended in Dec. 2025 was $-4.25 Mil. Celyad Oncology's Revenue for the six months ended in Dec. 2025 was $0.01 Mil. Therefore, Celyad Oncology's OCF Margin % for the quarter that ended in Dec. 2025 was -53,075.00%.

As of today, Celyad Oncology's current OCF Yield % is -59.29%.

The historical rank and industry rank for Celyad Oncology's OCF Margin % or its related term are showing as below:

CLYYF' s OCF Margin % Range Over the Past 10 Years
Min: -553300   Med: -8978.84   Max: -246.62
Current: -33425

During the past 13 years, the highest OCF Margin % of Celyad Oncology was -246.62%. The lowest was -553300.00%. And the median was -8978.84%.

CLYYF's OCF Margin % is ranked worse than
96.77% of 959 companies
in the Biotechnology industry
Industry Median: -66.52 vs CLYYF: -33425.00

Celyad Oncology OCF Margin % Related Terms

Celyad Oncology OCF Margin % Historical Data

* Premium members only.

The historical data trend for Celyad Oncology's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celyad Oncology OCF Margin % Chart

Celyad Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -14,935.14 -3,050.26 -32,320.00

Celyad Oncology Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11,893.65 -20,313.33 -1,657.22 -23,600.00 -53,075.00

CLYYF vs VRTX, REGN, ALNY: OCF Margin % Comparison

For the Biotechnology subindustry, Celyad Oncology's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celyad Oncology OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celyad Oncology's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Celyad Oncology's OCF Margin % falls into.


CLYYF
28GF Score
Celyad Oncology SA CLYYF
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celyad Oncology OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Celyad Oncology's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-8.08/0.025
=-32,320.00 %

Celyad Oncology's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-4.246/0.008
=-53,075.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -53,075.00% mean?
Celyad Oncology (CLYYF) has a OCF Margin % of -53,075.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Celyad Oncology and its competitors. According to the industry distribution chart, Celyad Oncology ranks #928 out of 959 companies in the Biotechnology industry, placing it in the top 96.8%.
Is Celyad Oncology's OCF Margin % too high?
Celyad Oncology's current OCF Margin % is -53,075.00%. Based on the distribution chart, Celyad Oncology ranks #928 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Celyad Oncology has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celyad Oncology's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Celyad Oncology ranks #928 out of 959 companies for OCF Margin %. This places Celyad Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Celyad Oncology and its competitors. Celyad Oncology's current OCF Margin % is -53,075.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celyad Oncology stock overvalued right now?
Based on GuruFocus' analysis, Celyad Oncology (CLYYF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $0.25 — trading 66.7% above its estimated fair value. The current OCF Margin % is -53,075.00%. Celyad Oncology's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Celyad Oncology (CLYYF), the current OCF Margin % is -53,075.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celyad Oncology (CLYYF) Overvalued in 2026?

Based on GuruFocus' analysis, Celyad Oncology stock appears to be overvalued. The current stock price of $0.25 is trading 66.7% above its estimated GF Value™ of $0.15. GuruFocus considers Celyad Oncology to be Significantly Overvalued.

Key valuation signals for CLYYF:

  • OCF Margin %: -53,075.00%
  • GF Value™: $0.15 vs. price of $0.25 (66.7% above fair value)
  • GF Score™: 28/100 with 6 warning signs

No single metric tells the full story. See the CLYYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celyad Oncology Business Description

Address Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
28GF Score

Get the complete analysis for CLYYF

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price
$0.15
GF Value